OCGN Ocugen (OCGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001372299
C-suite buying · 1Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
88
13F, latest reported quarter
What the filings say about OCGN
Insiders, 180 days
-$1.1M net sold
1 buyer · 1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.1M
2 notices
Ocugen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Ocugen, Inc. insiders sold a net $1.1M of stock across 44 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 9, 2026.
- The trade is 11.7% of the 4,018,470 shares held after it.
- No other insider sold within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Musunuri Shankar sold about $445.3K of OCGN under a 10b5-1 plan on Oct 9, 2026; 88 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Sep 9, 2026.
- The trade is 5.6% of the 1,030,771 shares held after it.
- No other insider sold within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Musunuri Shankar sold about $54.4K of OCGN under a 10b5-1 plan on Oct 9, 2026; 88 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Feb 16, 2023.
- The trade is 10.4% of the 4,487,197 shares held after it.
- No other insider sold within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Musunuri Shankar sold about $525.0K of OCGN under a 10b5-1 plan on Sep 9, 2026, the largest insider sale at the company since 2021; 88 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Feb 16, 2023.
- The trade is 5.3% of the 1,088,035 shares held after it.
- No other insider sold within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Musunuri Shankar sold about $64.1K of OCGN under a 10b5-1 plan on Sep 9, 2026, the largest insider sale at the company since 2023; 88 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.0% of the 521,000 shares held after it.
- No other insider bought within 30 days.
- 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Johnson-Greene Treerita Essalima bought about $25.8K of OCGN on Jun 15, 2026, the largest insider purchase at the company since 2023; 88 funds added in the latest 13F quarter.44 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.1M over 180 days
-$1.1M over 90 days
below 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
88 funds bought in last quarter
more than 64% of Pharma & Biotech
Revenue
+8.8% year over year
more than 58% of Pharma & Biotech
Margin
-1537.4% net margin
below 90% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
32.0% of the float short (float per yahoo 2026-10-27) · 15.8 days to cover · settled 2026-10-15
more than 99% of Pharma & Biotech
What changed in the last 30 days
Oct 13Chief Executive Officer Musunuri Shankar sold $499.7K under a 10b5-1 plan (Oct 9)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 9Officer Shankar Musunuri filed to sell $498.0K by Oct 9 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch OCGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OCGN: institutional holders (13F)
13F holdings, latest reported quarter
27,002,933 sh
$41.3M
21,469,307 sh
$32.8M
14,372,598 sh
$22.0M
13,943,252 sh
$21.3M
8,871,013 sh
$13.6M
Congress trades in OCGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OCGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Shankar Musunuri
Filed 2026-10-09
$498.0K
Shankar Musunuri
Filed 2026-09-09
$589.7K
OCGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$890.3K position · as of 2026-07-31
0.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$21.4M position · as of 2026-06-30
0.2%
PROFUND VP BIOTECHNOLOGY
$94.9K position · as of 2026-06-30
0.2%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$164.0K position · as of 2026-07-31
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
$584.6K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$1.8M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 6 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 3
2 active
1
Not applicable
0 active
4
Multi-phase
3 active
What changed recently
Expanded Access Program for RP in Adults
2026-10-03 · Available → No Longer Available
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.1M sold by insiders over 180 days, 88 funds added last quarter, $1.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
OCGN financials
Revenue growth
+8.8%
XBRL, annual
Net margin
-1537.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OCGN
| FY Dec 2025 | $4.4M |
| FY Dec 2024 | $4.1M |
| FY Dec 2023 | $6.0M |
| FY Dec 2022 | $2.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.5M |
| Mar 2026 | $1.5M |
| Dec 2025 | -$193.0K |
| Sep 2025 | $1.8M |
| Jun 2025 | $1.4M |
| Mar 2025 | $1.5M |
| Dec 2024 | $764.0K |
| Sep 2024 | $1.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-1,790%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OCGN
| FY Dec 2025 | -1,541% |
| FY Dec 2024 | -1,332% |
| FY Dec 2023 | -1,044% |
| FY Dec 2022 | -3,489% |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,672% |
| Mar 2026 | -1,251% |
| Dec 2025 | n/a |
| Sep 2025 | -1,144% |
| Jun 2025 | -1,073% |
| Mar 2025 | -1,036% |
| Dec 2024 | -1,810% |
| Sep 2024 | -1,142% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$61.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OCGN
| FY Dec 2025 | -$57.1M |
| FY Dec 2024 | -$45.5M |
| FY Dec 2023 | -$72.5M |
| FY Dec 2022 | -$64.5M |
| FY Dec 2021 | -$48.9M |
| Jun 2026 | -$12.2M |
| Mar 2026 | -$21.8M |
| Dec 2025 | -$14.0M |
| Sep 2025 | -$13.0M |
| Jun 2025 | -$10.8M |
| Mar 2025 | -$19.4M |
| Dec 2024 | -$10.4M |
| Sep 2024 | -$11.8M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity OCGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.97x |
| FY Dec 2023 | 0.07x |
| FY Dec 2022 | 0.03x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | n/a |
| Mar 2026 | 5.03x |
| Dec 2025 | n/a |
| Sep 2025 | 8.04x |
| Jun 2025 | 9.18x |
| Mar 2025 | 1.74x |
| Dec 2024 | 0.97x |
| Sep 2024 | 0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-34.80x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt OCGN
| FY Dec 2025 | -1.98x |
| FY Dec 2024 | -1.47x |
| FY Dec 2023 | -22.16x |
| FY Dec 2022 | -26.25x |
| FY Dec 2021 | -28.00x |
| Jun 2026 | -34.80x |
| Mar 2026 | -2.03x |
| Dec 2025 | -1.98x |
| Sep 2025 | -1.88x |
| Jun 2025 | -1.85x |
| Mar 2025 | -1.84x |
| Dec 2024 | -1.47x |
| Sep 2024 | -14.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity OCGN
| FY Dec 2025 | -778.7% |
| FY Dec 2024 | -153.9% |
| FY Dec 2023 | -110.0% |
| FY Dec 2022 | -105.1% |
| FY Dec 2021 | -103.5% |
| Jun 2026 | n/a |
| Mar 2026 | -661.4% |
| Dec 2025 | -778.7% |
| Sep 2025 | -289.7% |
| Jun 2025 | -569.4% |
| Mar 2025 | -248.7% |
| Dec 2024 | -153.9% |
| Sep 2024 | -112.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-92.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OCGN
| FY Dec 2025 | -108.0% |
| FY Dec 2024 | -73.5% |
| FY Dec 2023 | -72.8% |
| FY Dec 2022 | -81.0% |
| FY Dec 2021 | -87.7% |
| Jun 2026 | -92.2% |
| Mar 2026 | -118.4% |
| Dec 2025 | -108.0% |
| Sep 2025 | -107.0% |
| Jun 2025 | -120.9% |
| Mar 2025 | -98.8% |
| Dec 2024 | -73.5% |
| Sep 2024 | -74.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital OCGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-515.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OCGN
| FY Dec 2025 | -154.7% |
| FY Dec 2024 | -101.1% |
| FY Dec 2023 | -102.7% |
| FY Dec 2022 | -99.6% |
| FY Dec 2021 | -94.7% |
| Jun 2026 | -515.5% |
| Mar 2026 | -158.2% |
| Dec 2025 | -154.7% |
| Sep 2025 | -143.3% |
| Jun 2025 | -190.4% |
| Mar 2025 | -136.9% |
| Dec 2024 | -101.1% |
| Sep 2024 | -103.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing OCGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$141.8M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value OCGN
| FY Dec 2025 | $431.9M |
| FY Dec 2024 | $247.5M |
| FY Dec 2023 | $110.8M |
| FY Dec 2022 | $209.3M |
| FY Dec 2021 | $813.0M |
| Jun 2026 | $419.6M |
| Mar 2026 | $590.8M |
| Dec 2025 | $431.9M |
| Sep 2025 | $477.8M |
| Jun 2025 | $284.3M |
| Mar 2025 | $196.0M |
| Dec 2024 | $247.5M |
| Sep 2024 | $272.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-25.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield OCGN
| FY Dec 2025 | -13.6% |
| FY Dec 2024 | -19.4% |
| FY Dec 2023 | -49.2% |
| FY Dec 2022 | -22.7% |
| FY Dec 2021 | -5.4% |
| Jun 2026 | -11.8% |
| Mar 2026 | -10.0% |
| Dec 2025 | -13.6% |
| Sep 2025 | -11.2% |
| Jun 2025 | -18.5% |
| Mar 2025 | -25.2% |
| Dec 2024 | -19.4% |
| Sep 2024 | -17.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing OCGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2023-09 | |
|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | n/a |
| Operating income | -$62.9M | -$54.8M | -$65.5M | n/a |
| Net income | -$68.0M | -$54.0M | -$63.0M | n/a |
| EPS (diluted) | n/a | n/a | -0.26 | n/a |
| Operating cash flow | -$57.0M | -$42.1M | -$62.1M | n/a |
| Cash | $18.6M | n/a | $39.5M | $53.5M |
| Long-term debt | $27.5M | $27.3M | $2.8M | $1.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
OCGN Stock Sonar score 6/7 axes
Find similar shapesCompareOCGN ranks highest on insider conviction (62nd percentile) and growth (56th), and lowest on financial health (15th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OCGN filings, in plain words
Are Ocugen insiders buying or selling OCGN?
In the 180 days to 2026-10-28, Ocugen insiders were net sellers, a net $1.1M: $25.8K of purchases and $1.1M of sales reported on Form 4, by 1 buyer and 1 seller.
Are there planned insider sales of OCGN?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.1M of stock; the latest, by Shankar Musunuri, was filed 2026-10-09.
Read the full summary
In the 180 days to 2026-10-28, Ocugen insiders were net sellers of OCGN, a net $1.1M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Sales outweighed purchases more than tenfold by value. 100% of the 4 insider sales were made under a pre-arranged Rule 10b5-1 plan, so most selling was scheduled in advance. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
